Peptides Similar to Abaloparatide
Compare Abaloparatide with related peptides and alternatives
📌TL;DR
- •1 similar peptides identified
- •Teriparatide: Very High - Both are PTH1 receptor agonist peptides approved for osteoporosis at high fracture risk, administered as daily SC injections
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Abaloparatide (current) | - | - |
| Teriparatide | Very High - Both are PTH1 receptor agonist peptides approved for osteoporosis at high fracture risk, administered as daily SC injections | Abaloparatide is a PTHrP analog with RG-selective binding, while teriparatide is PTH(1-34) with more balanced RG/R0 binding. Abaloparatide shows superior total hip BMD gains and lower hypercalcemia rates. |
Peptides Related to Abaloparatide#
Abaloparatide belongs to the osteoanabolic therapeutic class, which includes agents that stimulate new bone formation through activation of osteoblast pathways. As a PTHrP(1-34) analog with RG-selective PTH1 receptor binding, abaloparatide is most directly comparable to teriparatide (PTH(1-34)), but should also be considered alongside romosozumab (anti-sclerostin antibody), which represents a different osteoanabolic mechanism.
Teriparatide (Forteo)#
Teriparatide is the first 34 amino acids of native human parathyroid hormone, developed by Eli Lilly and approved as Forteo in November 2002. It was the first osteoanabolic agent approved for osteoporosis and remains the most widely used bone-forming therapy.
Mechanism comparison: Both agents activate PTH1R to stimulate osteoblast-mediated bone formation. The key difference is receptor binding selectivity: abaloparatide preferentially engages the RG (signaling) conformation producing transient cAMP responses, while teriparatide binds both RG and R0 (prolonged signaling) conformations more equally, producing longer-lasting cAMP signals that stimulate both bone formation and bone resorption.
Clinical efficacy -- head-to-head data: The ACTIVE trial directly compared abaloparatide 80 mcg daily versus teriparatide 20 mcg daily (open-label) over 18 months:
| Endpoint | Abaloparatide | Teriparatide |
|---|---|---|
| Lumbar spine BMD change | +9.2% | +10.5% |
| Total hip BMD change | +2.9% (P<0.05 vs TPTD) | +2.0% |
| Femoral neck BMD change | +3.4% | +2.7% |
| Hypercalcemia | 3.4% | 6.4% |
| Injection site reactions | 16% | 7% |
Abaloparatide demonstrated statistically superior total hip BMD gains compared to teriparatide, while lumbar spine gains were comparable. The lower hypercalcemia rate with abaloparatide is consistent with its RG-selective binding profile.
Indications: Teriparatide has broader approved indications, including postmenopausal osteoporosis, male osteoporosis, and glucocorticoid-induced osteoporosis. Teriparatide also has 20+ years of clinical experience and post-marketing data. Its original osteosarcoma boxed warning was removed in 2020, and the 2-year treatment duration limitation was also removed.
Key trade-off: Abaloparatide offers superior hip BMD gains and lower hypercalcemia, while teriparatide has broader indications, more extensive long-term data, and lower injection site reaction rates.
| Parameter | Abaloparatide | Teriparatide |
|---|---|---|
| Parent peptide | PTHrP(1-34) | PTH(1-34) |
| Receptor selectivity | RG-preferring | RG + R0 |
| FDA approval | 2017 | 2002 |
| Indications | PMO, male OP | PMO, male OP, GIO |
| Dosing | 80 mcg SC daily | 20 mcg SC daily |
| Total hip BMD gain | +2.9% (18 mo) | +2.0% (18 mo) |
| Hypercalcemia rate | 3.4% | 6.4% |
| Osteosarcoma warning | In labeling | Removed (2020) |
Romosozumab (Evenity)#
Romosozumab is a humanized monoclonal antibody (not a peptide) that inhibits sclerostin, a glycoprotein produced by osteocytes that negatively regulates bone formation. It was developed by Amgen/UCB and approved in 2019.
Mechanism comparison: While abaloparatide activates PTH1R to stimulate osteoblasts, romosozumab inhibits sclerostin to both stimulate bone formation and suppress bone resorption simultaneously -- a dual-action mechanism. This produces rapid, substantial BMD gains within 12 months.
Clinical efficacy: Romosozumab 210 mg SC monthly produces larger BMD gains than either teriparatide or abaloparatide at 12 months (lumbar spine +13% vs +9-10%), reflecting the dual-action mechanism. The ARCH trial demonstrated that romosozumab followed by alendronate was superior to alendronate alone for fracture reduction.
Safety: Romosozumab carries a boxed warning for cardiovascular events (MI, stroke) based on a signal in the ARCH trial. This is distinct from the osteosarcoma consideration for PTH1R agonists. Romosozumab is contraindicated in patients who have had a MI or stroke within the preceding 12 months.
Key trade-off: Romosozumab may produce greater and faster BMD gains, but carries a cardiovascular safety signal that limits use in patients with CVD risk. Abaloparatide has no cardiovascular safety concern but produces slower BMD accrual.
Summary Comparison#
| Feature | Abaloparatide | Teriparatide | Romosozumab |
|---|---|---|---|
| Drug class | PTHrP analog | PTH analog | Anti-sclerostin mAb |
| Mechanism | PTH1R agonist (RG) | PTH1R agonist (RG+R0) | Sclerostin inhibitor |
| Route | SC daily | SC daily | SC monthly |
| Duration | Up to 2 years | No limit (2020 update) | 12 months |
| Lumbar spine BMD | +9.2% (18 mo) | +10.5% (18 mo) | +13% (12 mo) |
| Total hip BMD | +2.9% (18 mo) | +2.0% (18 mo) | +4-6% (12 mo) |
| Key safety concern | ISRs, hypercalcemia | Hypercalcemia | CV events (MI, stroke) |
| Sequential therapy | Demonstrated (ACTIVExtend) | Demonstrated | Standard practice |
Clinical Decision Considerations#
The choice among osteoanabolic agents depends on several patient-specific factors:
- Cardiovascular risk: Romosozumab is contraindicated in patients with recent MI or stroke; abaloparatide and teriparatide do not have this restriction
- Hypercalcemia risk: Abaloparatide has lower hypercalcemia rates than teriparatide
- Hip BMD priority: Abaloparatide demonstrated superior total hip gains versus teriparatide
- Glucocorticoid-induced osteoporosis: Teriparatide is the only osteoanabolic with formal GIO approval
- Treatment experience: Teriparatide has the longest clinical track record (since 2002)
Related Reading#
Frequently Asked Questions About Abaloparatide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer